HTA ID Drug Brand Indication Assessment status Date
- Aflibercept Eylea® For the treatment of neovascular (wet) age-related macular degeneration (AMD). Rapid Review Complete 21st December 2012
- Decitabine Dacogen® For AML in patients who are >65yrs who are not candidates for standard induction therapy Rapid review complete 21st December 2012
- Eribulin Halaven® For the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Assessment process complete 7th December 2012
- Ingenol mebutate Picato® For cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (AK) in adults. Rapid Review Complete 6th December 2012